January 23, 2018
Alexion Pharmaceuticals, Inc. today announced that Deborah Dunsire, M.D. has been appointed to the Company’s Board of Directors as a new independent director. Dr. Dunsire is a proven leader in the biopharmaceutical industry with three decades of experience and a successful track record of growing..
For years, hospital executives have expressed frustration when essential drugs like heart medicines have become scarce, or when prices have skyrocketed because investors manipulated the market. Now, some of the country’s largest hospital systems are taking an aggressive step to combat the problem: They plan..
CEO Richard Gonzalez has made it clear he expects new oncology drugs to fill the yawning revenue gap AbbVie will experience with the loss of Humira patent protection. The company is prepping for that day with a $139 million expansion at a plant in Ireland..
French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases. The move comes at a time of renewed interest by large drugmakers..
Fiona Marshall, Ph.D., is set to leave Sosei. Marshall has served as CSO of the company since it bought Heptares but is now departing to take on a senior role at another business. Sosei responded to the resignation of Marshall—who will leave at the end..
Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year. Zurich, Switzerland-based Inositec hired van Alphen away from Roche,..
The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark’s Novo Nordisk as too low but would be willing to consider a higher figure. Van Herk Investments, which owns about 10.2 percent of Ablynx, said it..
While Big Pharma companies have equivocated about whether to pull drug production from the U.K. because of Brexit, CDMO Almac quickly went out and did something about it. It obtained a site in the EU and is now investing about $30 million on upgrades. Based..
January 18, 2018
Chinese bidders are circling a diabetes care business owned by the world’s largest health-care company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters. New Brunswick, N.J.-based J&J said in January last year it..
January 18, 2018
After shepherding Forma Therapeutics from its discovery stage to clinical trials as its R&D chief, John Hohneker is joining Anokion Therapeutics as president and CEO, effective Jan. 22. “John brings tremendous experience in biologics development to Anokion, including in the immunology space. His broad leadership..